The Healthcare sector is made up of devices and systems that support healthcare organizations such as hospitals, doctor’s offices, surgical centers, and more. Healthcare technologies range from equipment like imaging machinery and robotic surgical assistants to patient recordkeeping applications and scheduling support. Register today to discover how Forge can help you buy and sell private shares.
Register to add companies to your watchlist and get access to bids/asks activity, last matched price and trade eligibility details.
Register| Active Market | Forge Price1 | Last Funding Round | Trade Eligibility | ||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Company | Sector & Subsector | Market Activity4 |
Highest Bid | Lowest Ask | Last Matched | +/- to LFR | $ Total Bids | $ Total Asks | # Bids | # Asks | Current Price |
6-month |
1-year |
Total Funding |
Round | Date | Amount Raised |
Post-Money Valuation3 |
Price |
Key Investors | Common | Preferred | Fund | ||
| Alma | Healthcare Digital Health | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | $441.06MM | Series D | 8/25/2022 | $130MM | $788.56MM | $17.52 | Thoma Bravo, Cigna Ventures, Insight Partners, Optum Ventures, Tusk Venture Partners, Primary Venture Partners, Sound Ventures | |||||
| Alterome Therapeutics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | $231.07MM | Series B | 4/3/2024 | $132MM | $356.19MM | $4.08 | Goldman Sachs Alternatives, Canaan Partners, Invus, Driehaus Capital Management, Digitalis Ventures, Blue Owl Capital, OrbiMed, Nextech Invest, Vida Ventures, Boxer Capital, Colt Ventures | |||||
| Alto Neuroscience | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | $253.17MM | Series C | 11/21/2023 | $50.31MM | $235.65MM | $4.71 | InVivium Capital, Franklin Templeton, Point72, Eli Lilly and Company, Alexandria Venture Investments, Alpha Wave Ventures, Lightswitch Capital, Alkeon Capital, WhatIf Ventures, Windham Venture Partners | |||||
| BlueRock Therapeutics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | -- | Not available | -- | -- | -- | -- | -- | |||||
| Cambrian | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | $299.72MM | Series C | 10/26/2021 | $100.78MM | $486.23MM | $6.95 | Anthos Capital, SALT Fund, Apeiron Investment Group, Future Ventures, Moore Capital | |||||
| Cerebral | Healthcare Digital Health | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | $25MM | Series D | 9/12/2025 | $25MM | $407.5MM | $2.50 | Undisclosed Investors | |||||
| Chroma Medicine | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | $262MM | Series B | 3/1/2023 | $135MM | $450.56MM | $2.60 | ARCH Venture Partners, DCVC Bio, Mubadala Capital, Sixth Street, Alexandria Venture Investments, Atlas Venture, Casdin Vapital, Cormorant Asset Management, Janus Henderson Investors, Newpath Partners, Omega Funds, Osage University Partners, Sofinnova Partners, T Rowe Price, Wellington Management | |||||
| Covera Health | Healthcare Healthcare Software | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | $180.66MM | Series C-3 | 4/10/2026 | $27.35MM | $179.98MM | $1.74 | Undisclosed Investors | |||||
| Doctor on Demand | Healthcare Digital Health | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | $239.67MM | Series D | 7/8/2020 | $78.74MM | $820.61MM | $28.53 | General Atlantic | |||||
| Evonetix | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | -- | Not available | -- | -- | -- | -- | -- | |||||
| Galileo Health | Healthcare Healthcare Providers & Services | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | $235.81MM | Series E-2 | 6/23/2025 | $25.95MM | $399.66MM | $4.57 | Undisclosed Investors | |||||
| Kailera Therapeutics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | $959.96MM | Series B | 10/14/2025 | $603.18MM | $1.4B | $14.00 | Bain Capital, Adage Capital Management, Canada Pension Plan Investment Board, Invus, Janus Henderson Investors, Perseverance Capital, QIA, Royalty Pharma, Surveyor Capital, T. Rowe Price, Atlas Venture, Bain Capital Life Sciences, RTW Investments, Sirona Capital | |||||
| Pelago | Healthcare Digital Health | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | $478.23MM | Series C | 3/28/2024 | $58MM | $349.85MM | $17.55 | Atomico, Kinnevik AB, Octopus Ventures, Y Combinator, Eight Roads, GreyMatter Capital | |||||
| Potrero Medical | Healthcare Other Healthcare | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | -- | Not available | -- | -- | -- | -- | -- | |||||
| Scribe Therapeutics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | $121.16MM | Series B | 3/31/2021 | $100.45MM | $300.86MM | $6.05 | Avoro Ventures, Avoro Capital Advisors, OrbiMed Advisors, Andreessen Horowitz, Perceptive Advisors, T. Rowe, Wellington Management, RA Capital Management, Menlo Venture | |||||
| SHINE Medical Technologies | Healthcare Other Healthcare | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | -- | Not available | -- | -- | -- | -- | -- | |||||
| Suki | Healthcare Healthcare Software | Low | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | $488.15MM | Series D | 10/10/2024 | $50MM | $283.39MM | $4.59 | Hedosophia, Venrock, March Capital, Flare Capital, Breyer Capital, inHealth Ventures | |||||
| Transcarent | Healthcare Healthcare Providers & Services | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | $1.13B | Series D-1 | 4/7/2025 | $700MM | $3.16B | $20.48 | Undisclosed Investors | |||||
| Turquoise Health | Healthcare Healthcare Providers & Services | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | $96.49MM | Series C | 3/17/2026 | $36.46MM | $314.03MM | $11.72 | Oak HC/FT, Andreessen Horowitz, Adams Street Partners, Yosemite | |||||
| UpStream | Healthcare Healthcare Software | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | $185MM | Series B | 10/6/2022 | $120MM | $781.85MM | $2.71 | Coatue, Dragoneer Investment Group, Avidity Partners, Define Ventures, Mubadala | |||||
| BioTissue | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | -- | Not available | -- | -- | -- | -- | -- | |||||
| Casma Therapeutics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | -- | Not available | -- | -- | -- | -- | -- | |||||
| Cleerly | Healthcare Digital Health | Low | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | $386.48MM | Series C | 12/4/2024 | $330.08MM | $729.01MM | $11.78 | T. Rowe Price Associates, Fidelity Management, Sands Capital, Piper Sandler, Heartland Healthcare Capital funds, Mirae Asset Capital, Peter Thiel, Breyer Capital, Novartis, Pura Vida Investments, Vensana Capital, LRVHealth, New Leaf Ventures, Cigna Ventures, DigiTx Partners, Insight Partners, Battery Ventures | |||||
| Evommune | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | $268.46MM | Series C | 10/31/2024 | $115.5MM | $346.35MM | $1.59 | RA Capital Management, Sectoral Asset Management, B Capital, Marshall Wace, Avego Bioscience Capital, Longwood Fund, RTW Investments, ADAR1 Capital Management, NEXTBio Capital, Beiersdorf Venture Capital, FemHealth Ventures, Allostery Investments LP, Pivotal bioVenture Partners, EQT Life Sciences, Andera Partners, Amplitude Ventures, SymBiosis, Verition Fund Management | |||||
PLEASE READ THESE IMPORTANT LEGAL NOTICES & DISCLOSURES
Forge Price™ is a custom data-point calculated and disseminated by Forge Data LLC (“Forge Data”) and is a mark of Forge Data. Forge Price may rely on a very limited number of inputs in its calculation. Forge Price is prepared and disseminated solely for informational purposes. Redistribution is permitted solely with Forge’s written consent. While Forge has obtained information from sources it believes to be reliable, Forge does not perform an audit or undertake any duty of due diligence or independent verification of any information it receives. Forge does not guarantee the accuracy, completeness, timeliness, or availability of Forge Price, and are not responsible for any errors or omissions, regardless of the cause, or any results obtained from the use of Forge Price. Forge Price is derived from secondary activity on the Forge platform and other private market trading platforms, and other publicly-available datapoints collected by Forge. Forge Price is not intended to, and does not necessarily, represent the market price of any securities (I.e., the price at which you could buy or sell such securities). Neither reference to company names, nor calculation of Forge Price for a specific company, implies any affiliation between Forge and that company, any endorsement or sponsorship by Forge of any company or vice versa, or any partnership, joint venture or other commercial relationship between Forge and any company. Rights with respect to any company marks referred to herein are owned by the company. The dollar-figure and percentage displayed indicates the per share change in dollar amount and percentage since the most recent Forge Price change. Percentages are rounded to the nearest whole number.
The dollar-figure and percentage displayed indicates the per share change in dollar amount and percentage since the most recent Forge Price change. Percentages are rounded to the nearest whole number.
Post-Money Valuation (valuation) represents the estimated valuation based on company-submitted Certificates of Incorporations (COIs).
Market activity indicates the level of activity for a company based on recent IOIs, secondary transactions, and pending transactions.
Sector and subsector descriptions focus primarily on the types of companies within the respective sectors and subsectors that are typically available through Forge Markets. Any sector or subsector as a whole may include companies that participate in business lines in other sectors or subsectors. Companies are classified into sectors and subsectors according to the problem(s) they seek to solve rather than the method by which the solution is delivered.